Sequential Cytoreduction and Allogeneic Cell Therapy
Learn More About This Topic: Chat with Us | Email Us
Sequential Cytoreduction and Allogeneic Cell Therapy for Patients with Multiple Myeloma and Lymphoma
Summary
This study tests the effectiveness of a protocol which uses low doses of radiation and chemotherapy in stem cell transplant with multiple myeloma or lymphoma when it is performed following a traditional high dose chemotherapy and autologous stem cell transplant. This protocol is available to patients meeting eligibility requirements under the Stem Cell Transplant Program at Midwestern Regional Medical Center.
Requirements
- Patients with a diagnosis of multiple myeloma or lymphoma
- Patients with MM must be between 18 and 70 years of age, 18-65 for lymphoma patients
- Patients must have a healthy and available HLA-matched sibling donor
For More Information:
Please contact one of our Oncology Information Specialists at 1-800-615-3055 to learn more about this clinical trial. Oncology Information Specialists are available 24 hours a day, 7 days a week, 365 days a year.
